A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) via Subcutaneous (SC) Injection of MK-3475A (Pembrolizumab Formulated With MK-5180) In Advanced Solid Tumors (MK-3475A-C18)

Trial Identifier: 3475A-C18
Sponsor: MSD
Start Date: September 2021
Primary Completion Date: September 2026
Study Completion Date: September 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary - English

Trial Locations

Country Location
Chile, Araucania Temuco, Araucania, Chile, 4800827
Chile, Region M. de Santiago Santiago, Region M. de Santiago, Chile, 8420383
Chile, Region M. de Santiago Santiago, Region M. de Santiago, Chile, 7500921
Hungary, Budapest Budapest, Hungary, 1062
Hungary, Pest Budapest, Pest, Hungary, 1122
Japan, Fukuoka Fukuoka, Japan, 811-1395
Japan, Osaka Hirakata, Osaka, Japan, 573-1191
Japan, Osaka Osaka, Japan, 541-8567
Japan, Saitama Ina-machi, Saitama, Japan, 362-0806
Japan, Shizuoka Nagaizumi-cho,Sunto-gun, Shizuoka, Japan, 411-8777
Korea, Republic of, Seoul Seoul, Korea, Republic of, 06351
Korea, Republic of, Seoul Seoul, Korea, Republic of, 03722
South Africa, Eastern Cape Port Elizabeth, Eastern Cape, South Africa, 6055
South Africa, Gauteng Johannesburg, Gauteng, South Africa, 2196
South Africa, Gauteng pretoria, Gauteng, South Africa, 0181
South Africa, Gauteng Pretoria, Gauteng, South Africa, 0001
South Africa, Gauteng Sandton, Gauteng, South Africa, 2196
South Africa, Western Cape Cape Town, Western Cape, South Africa, 7570
South Africa, Western Cape Rondebosch, Western Cape, South Africa, 7700
Spain, Andalucia Málaga, Andalucia, Spain, 29010
Spain, Cataluna Barcelona, Cataluna, Spain, 08036
Spain, Madrid, Comunidad de MADRID, Madrid, Comunidad de, Spain, 28009